ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2024, Vol. 33 ›› Issue (1): 29-35.DOI: 10.3969/j.issn.1006-298X.2024.01.005

• 论著 • 上一篇    下一篇

高钾血症对维持性血液透析患者3月内全因死亡及心血管疾病死亡的影响

  

  • 出版日期:2024-02-28 发布日期:2024-02-27

Hyperkalemia on all-cause and cardiovascular disease mortality within 3 months in maintenance hemodialysis patients

  • Online:2024-02-28 Published:2024-02-27

摘要: 目的:多中心回顾性队列研究血钾水平对维持性血液透析(MHD)患者3月内全因死亡及心血管疾病(CVD)死亡的影响。
方法:选择2010-01-01~2019-12-31浙江省透析质控中心登记系统中新入的成人MHD患者。收集一般资料及实验室指标。根据MHD随访终点前3月内透析前血钾的最高值,将患者分为8组,应用Kaplan-Meier法比较各组患者全因死亡和CVD死亡之间的生存差异,采用多因素COX回归分析血钾水平与全因死亡及CVD死亡的相关性。
结果:共纳入患者21 861例,其中男性13 465例(61.6%),平均年龄(61.1±15.4)岁,10 132例(46.3%)患者合并CVD。中位随访时间34(19,56)月,发生全因死亡4 635例(21.2%),其中CVD 1 319例(6.0%)。血钾水平<3.5 mmol/L患者759例(3.5%),血钾水平≥5.0 mmol/L患者9 782例(44.7%),血钾水平≥5.5 mmol/L患者5 420例(24.7%)。Kaplan-Meier生存曲线显示,不同血钾水平组全因死亡风险(Log-rank检验, χ2=248.0,P<0.001)、CVD死亡风险(Log-rank检验, χ2=96.6,P<0.001)差异均有统计学意义。多因素COX回归分析显示,血钾水平≥5.5 mmol/L是MHD患者3月内全因死亡(5.5≤血钾<6.0 mmol/L,HR=1.34 95%CI 1.08~1.67,P=0.008;6.0≤血钾<6.5 mmol/L,HR=1.53,95%CI 1.18~2.00,P=0.001;血钾≥6.5 mmol/L,HR=2.33,95%CI 1.80~3.01,P<0.001)和CVD死亡(5.5≤血钾<6.0 mmol/L,HR=1.65,95%CI 1.13~2.43,P=0.001;6.0≤血钾<6.5 mmol/L,HR=1.75,95%CI 1.08~2.82,P=0.023;血钾≥6.5 mmol/L,HR=2.70,95%CI 1.70~4.29,P<0.001)的独立危险因素。
结论:MHD患者透析前高血钾发生率为24.7%,是患者3月内全因死亡和CVD死亡的独立危险因素,且血钾水平越高,死亡风险越大。


关键词: 血液透析, 血钾, 死亡率, 心血管疾病

Abstract: Objective:To investigate the effect of serum potassium concentrations on all-cause mortality and cardiovascular disease (CVD) mortality within 3 months in maintenance hemodialysis (MHD) patients.
Methodology:A multicenter retrospective cohort study. The general information and laboratory indicators of patients newly entered MHD in the registration system of Zhejiang province dialysis quality control center from January 1, 2010 to December 31, 2019 were collected. Serum potassium was selected as the highest value of serum potassium before dialysis within 3 months before the end of follow-up. The patients were divided into 8 groups according to the serum potassium level, and the Kaplan-Meier method was used to compare the survival differences between all-cause mortality and CVD mortality in each group, and the multivariate COX regression model was used to analyze the relationship between serum potassium level and all-cause mortality and CVD mortality.
Results:A total of 21 861 patients aged (61.1±15.4) years old were included, including 13 465 males (61.6%), and 10 132 patients (46.3%) with cardiovascular diseases. The median follow-up time was 34(19, 56) months, 4 635 cases (21.2%) all-cause died, including 1 319 cases (6.0%) with cardiovascular disease. 759 patients (3.5%) with serum potassium<3.5 mmol/L, 9 782 patients (44.7%) with serum potassium≥5.0 mmol/L, and 5 420 patients (24.7%) with serum potassium≥5.5 mmol/L. Kaplan-Meier survival curve showed that the risk of all-cause mortality (Log-rank test, χ2=248.0, P<0.001), and the risk of cardiovascular mortality (Log-rank test, χ2=96.6, P<0.001) were significantly different among eight groups. Multivariate COX regression analysis showed that serum potassium level≥5.5 mmol/L was an independent risk factor for all-cause mortality(5.5≤K<6.0 mmol/L, HR=1.34,95%CI 1.08~1.67,P=0.008;6.0≤K<6.5 mmol/L,HR=1.53,95%CI 1.18~2.00,P=0.001;K≥6.5 mmol/L,HR=2.33 95%CI 1.80~3.01,P<0.001) and CVD mortality(5.5≤K<6.0 mmol/L,HR=1.65,95%CI 1.13~2.43,P=0.001;6.0≤K<6.5 mmol/L,HR=1.75,95%CI 1.08~2.82,P=0.023;K≥6.5 mmol/L,HR=2.70,95%CI 1.70~4.29,P<0.001) within 3 months in MHD patients.
Conclusion:Serum potassium≥5.5 mmol/L was an independent risk factor for all-cause mortality and CVD mortality within 3 months in MHD patients, and the higher the serum potassium level, the greater the risk of death.


Key words: hemodialysis, serum potassium, mortality, cardiovascular disease